PHOENIX—Teva Pharmaceuticals has agreed to pay $285 million to settle litigation stemming from a southern Nevada hepatitis C outbreak allegedly caused by reuse of the company’s propofol vials at endoscopy centers, the drug maker announced Feb. 20 (Teva Parenteral Medicines Inc. v. Chanin).
The settlement includes 41 Nevada District Court cases, court spokeswoman Mary Ann Price told Bloomberg BNA Feb. 24. The lawsuits were filed by former patients at the Endoscopy Center of Southern Nevada and affiliated clinics.
Teva spokeswoman Denise Bradley told Bloomberg BNA in a Feb. 24 email the company “is pleased to have put the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.